First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases.
Thatcher Heumann(Vanderbilt University), Douglas Kondziolka(Neurological Surgery), Peter Wu(Leidos (United States)), Jeffrey S. Weber(NYU Langone Health), Akram A. Habibi(NYU Langone Health), Anna C. Pavlick(Cornell University), Marc Kryger(NYU Langone Health), Kenneth Bernstein(NYU Langone Health), Cameron Beaudreault(NYU Langone Health), Rebecca Ye(NYU Langone Health), Joshua S. Silverman(NYU Langone Health), Alexandra Sansosti(NYU Langone Health)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k